TrueMark Investments LLC Buys 3,807 Shares of Pfizer Inc. $PFE

TrueMark Investments LLC boosted its stake in Pfizer Inc. (NYSE:PFE) by 3.6% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 110,930 shares of the biopharmaceutical company’s stock after purchasing an additional 3,807 shares during the quarter. TrueMark Investments LLC’s holdings in Pfizer were worth $2,689,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also added to or reduced their stakes in PFE. GKV Capital Management Co. Inc. purchased a new stake in shares of Pfizer in the 1st quarter valued at about $27,000. North Capital Inc. purchased a new stake in shares of Pfizer in the 1st quarter valued at about $28,000. Bayforest Capital Ltd purchased a new stake in shares of Pfizer in the 1st quarter valued at about $28,000. Harbor Asset Planning Inc. purchased a new position in shares of Pfizer during the 2nd quarter valued at about $29,000. Finally, Horizon Financial Services LLC purchased a new position in shares of Pfizer during the 1st quarter valued at about $35,000. Institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the company. Citigroup raised their price objective on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a report on Wednesday, August 6th. Weiss Ratings reissued a “hold (c-)” rating on shares of Pfizer in a report on Wednesday, October 8th. Bank of America raised their price objective on Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a report on Friday, October 3rd. UBS Group reissued a “neutral” rating and set a $28.00 price objective on shares of Pfizer in a report on Wednesday, October 1st. Finally, Morgan Stanley decreased their price objective on Pfizer from $33.00 to $32.00 and set an “equal weight” rating on the stock in a report on Friday, October 10th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $28.13.

Pfizer Price Performance

Shares of Pfizer stock opened at $24.52 on Friday. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. The business’s 50 day simple moving average is $24.89 and its two-hundred day simple moving average is $24.11. The stock has a market capitalization of $139.38 billion, a P/E ratio of 13.04, a price-to-earnings-growth ratio of 0.81 and a beta of 0.55. Pfizer Inc. has a one year low of $20.92 and a one year high of $29.36.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. The business had revenue of $14.65 billion for the quarter, compared to analysts’ expectations of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business’s quarterly revenue was up 10.3% on a year-over-year basis. During the same period in the previous year, the firm earned $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.0%. The ex-dividend date is Friday, November 7th. Pfizer’s dividend payout ratio (DPR) is currently 91.49%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.